http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100318250-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-1833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-51 |
filingDate | 1998-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2002-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2002-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-100318250-B1 |
titleOfInvention | DNA vaccines for Hepatitis C Virus |
abstract | The present invention is to induce an optimal immune response against the envelope glycoproteins envelope 1 (E1) and envelope 2 (E2) and nonstructural proteins NS3, NS4 and NS5 using the DNA immune method , Internal ribosome entry sequence (IRS) such that granulocyte and macrophage-aggregation promoter factor genes (GM-CSF), together with the E1, E2 and NS genes of HCV, can be expressed in the same vector. By designing a delivery vector using the HCV DNA immunization method, it is possible to derive the optimal immune response to the E1, E2 and NS proteins of HCV. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101913674-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100471946-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150132885-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101868954-B1 |
priorityDate | 1998-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 207.